<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2546">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04347239</url>
  </required_header>
  <id_info>
    <org_study_id>CD12_COVID-19</org_study_id>
    <nct_id>NCT04347239</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)</brief_title>
  <official_title>A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CytoDyn, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CytoDyn, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of leronlimab (PRO 140)
      administered as weekly subcutaneous injection in subjects with severe or critical COVID-19
      disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2b/3, two-arm, randomized, double blind, placebo controlled, adaptive design
      multicenter study to evaluate the safety and efficacy of leronlimab (PRO 140) in patients
      with severe or critical symptoms of respiratory illness caused by coronavirus 2019 infection.
      Patients will be randomized to receive weekly doses of 700 mg leronlimab (PRO 140), or
      placebo. Leronlimab (PRO 140) and placebo will be administered via subcutaneous injection.

      The study will have three phases: Screening Period, Treatment Period, and Follow-Up Period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality at Day 28</measure>
    <time_frame>Day 28</time_frame>
    <description>Day 0 refers to the data of randomization/first treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality at Day 14</measure>
    <time_frame>Day 14</time_frame>
    <description>Day 0 refers to the data of randomization/first treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in clinical status of subject at Day 14 (on a 7 point ordinal scale)</measure>
    <time_frame>Day 14</time_frame>
    <description>A 7-category ordinal scale of patient health status ranges from: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in clinical status of subject at Day 28 (on a 7 point ordinal scale)</measure>
    <time_frame>Day 28</time_frame>
    <description>A 7-category ordinal scale of patient health status ranges from: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Sequential Organ Failure Assessment (SOFA) score at Day 14.</measure>
    <time_frame>Day 14</time_frame>
    <description>The SOFA score assessment will be based on PaO2/FiO2, platelets, Glasgow coma scale (GCS), bilirubin, Mean arterial pressure OR administration of vasoactive agents required, and Serum creatinine</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">390</enrollment>
  <condition>Coronavirus Disease 2019</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>700mg Leronlimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebos</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leronlimab (700mg)</intervention_name>
    <description>Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)</description>
    <arm_group_label>700mg Leronlimab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female adult ≥ 18 years of age at time of screening.

          2. Subjects hospitalized with severe or critical illness caused by coronavirus 2019
             infection as defined below:

             A. Severe Illness:

             - Diagnosed with COVID-19 by standard RT-PCR assay or equivalent testing within 5 days
             of screening

             AND

             Symptoms of severe systemic illness/infection with COVID-19:

             - At least 1 of the following: fever, cough, sore throat, malaise, headache, muscle
             pain, shortness of breath at rest or with exertion, confusion, or symptoms of severe
             lower respiratory symptoms including dyspnea at rest or respiratory distress

             AND

             Clinical signs indicative of severe systemic illness/infection with COVID-19, with at
             least 1 of the following:

             - RR ≥ 30, HR ≥ 125, SaO2 &lt;93% on room air or requires &gt; 2L oxygen by NC in order
             maintain SaO2 ≥93%, PaO2/FiO2 &lt;300

             AND

             - None of the following: Respiratory failure (defined by endotracheal intubation and
             mechanical ventilation, oxygen delivered by high-flow nasal cannula, noninvasive
             positive pressure ventilation, or clinical diagnosis of respiratory failure in setting
             of resource limitations), Septic shock (defined by SBP &lt; 90 mm Hg, or Diastolic BP &lt;
             60 mm Hg), Multiple organ dysfunction/failure

             B. Critical Illness:

             - Diagnosed with COVID-19 by standard RT-PCR assay or equivalent testing within 5 days
             of screening

             AND

             Evidence of critical illness, defined by at least 1 of the following:

             - Respiratory failure defined based on resource utilization requiring at least 1 of
             the following: Endotracheal intubation and mechanical ventilation, oxygen delivered by
             high-flow nasal cannula, noninvasive positive pressure ventilation, ECMO, or clinical
             diagnosis of respiratory failure (in setting of resource limitation)

             OR

             - Shock (defined by SBP &lt; 90 mm Hg, or Diastolic BP &lt; 60 mm Hg or requiring
             vasopressors)

             OR

             -Multiple organ dysfunction/failure

          3. Subject, if intubated, positive endexpiratory pressure (PEEP) &lt;15 cmH2O with PaO2/FiO2
             &gt;150 mmHg.

          4. Electrocardiogram (ECG) with no clinically significant findings as assessed by the
             Investigator

          5. Subject (or legally authorized representative) provides written informed consent prior
             to initiation of any study procedures.

          6. Understands and agrees to comply with planned study procedures.

          7. Women of childbearing potential and their partner must agree to use at least one
             highly effective method of contraception (e.g., hormonal contraceptives [implants,
             injectables, combination oral contraceptives, transdermal patches, or contraceptive
             rings], intrauterine devices, bilateral tubal occlusion, or sexual abstinence) for the
             duration of the study.

        Exclusion Criteria:

          1. Subjects with do-not-resuscitate (DNR) and/or do-not-intubate (DNI) orders or expected
             to be made DNR/DNI in setting of resource limitations or family wishes.

          2. Not a candidate for dialysis or continuation of care (or full medical support) in
             setting of resource limitations.

          3. Subject on continuous vasopressors (at the dose of norepinephrine &gt;20μg/min and/or
             vasopressin &gt;0.04 units/kg/min) for &gt;48 hours at time of screening.

          4. Subjects who have a history of allergic reactions attributed to compounds of similar
             chemical or biologic composition to leronlimab (PRO 140) are not eligible.

          5. Inability to provide informed consent or to comply with test requirements

          6. Consideration by the investigator, for safety reasons, that the subject is an
             unsuitable candidate to receive study treatment

          7. Pregnancy or breast feeding

          8. Subject participating in another study with for an investigational treatment for
             COVID-19.

        Note: Subject who were prescribed (1) hydroxychloroquine or chloroquine with or without
        azithromycin, (2) Remdesivir, (3) convalescent plasma therapy, or (4) immunomodulatory
        treatments (including but not limited to sarilumab, clazakizumab, tocilizumab, and
        anakinra) for the off-label treatment of COVID-19 prior to study enrollment may be included
        and may continue to receive these agents as part of standard-of-care.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kush Dhody, MBBS, MS, CCRA</last_name>
    <phone>301-956-2536</phone>
    <email>kushd@amarexcro.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Jude Medical Center</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blanca Sanchez</last_name>
      <phone>714-446-5620</phone>
      <email>Blanca.Sanchez@stjoe.org</email>
    </contact>
    <investigator>
      <last_name>David J Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Lopez</last_name>
      <phone>310-794-8043</phone>
      <email>NancyRLopez@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Otto Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Advanced Research &amp; Education (CARE)</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Recknor</last_name>
      <phone>770-534-5154</phone>
      <email>jrecknor@carega.net</email>
    </contact>
    <investigator>
      <last_name>Angela Ritter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caitlin Davis</last_name>
      <phone>617-735-4466</phone>
      <email>Cdavis6@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Sabrina Tan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Barnabas</name>
      <address>
        <city>Livingston</city>
        <state>New Jersey</state>
        <zip>07052</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Subroto Paul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlantic Health System Hospital</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962-1905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eric Whitman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Holy Name Medical Center</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patty Kiledjian</last_name>
      <phone>201-541-6312</phone>
      <email>pkiledjian@holyname.org</email>
    </contact>
    <investigator>
      <last_name>Benjamin De La Rosa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Wilson</last_name>
      <phone>718-920-7916</phone>
    </contact>
    <investigator>
      <last_name>Harish Seethamraju, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novant Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen O'Brien</last_name>
      <email>kathleen.obrien@novanthealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Pailing Richards</last_name>
      <phone>704-996-7627</phone>
      <email>pcrichards@novanthealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Morgan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio Health</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kiran Devulapally, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marcel Curlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Wang</last_name>
      <phone>214-818-2526</phone>
      <email>Samantha.wang@bswhealth.org</email>
    </contact>
    <investigator>
      <last_name>Uriel Sandkovsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hinali Zaveri, MD</last_name>
      <phone>713-873-2353</phone>
      <email>hzaveri@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Kalpalatha Guntupalli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordan Lake</last_name>
      <phone>713-500-6767</phone>
      <email>Jordan.e.lake@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Jordan Lake, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 13, 2020</study_first_submitted>
  <study_first_submitted_qc>April 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2020</study_first_posted>
  <last_update_submitted>August 28, 2020</last_update_submitted>
  <last_update_submitted_qc>August 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

